Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are neurodevelopmental disorders of genomic imprinting. AS results from loss of function of the ubiquitin protein ligase E3A (UBE3A) gene, whereas the genetic defect in PWS is unknown. Although induced pluripotent stem cells (iPSCs) provide invaluable models of human disease, nuclear reprogramming could limit the usefulness of iPSCs from patients who have AS and PWS should the genomic imprint marks be disturbed by the epigenetic reprogramming process. Our iPSCs derived from patients with AS and PWS show no evidence of DNA methylation imprint erasure at the cis-acting PSW imprinting center. Importantly, we find that, as in normal brain, imprinting of UBE3A is established during neuronal differentiation of AS iPSCs, with the paternal UBE3A allele repressed concomitant with up-regulation of the UBE3A antisense transcript. These iPSC models of genomic imprinting disorders will facilitate investigation of the AS and PWS disease processes and allow study of the developmental timing and mechanism of UBE3A repression in human neurons.antisense transcript | epigenetic | neuronal differentiation A ngelman syndrome (AS) is a neurogenetic disorder characterized by profound intellectual disability, absent speech, frequent seizures, motor dysfunction, and a characteristic happy demeanor (1, 2). Prader-Willi syndrome (PWS) is characterized hyperphagia/obesity; small stature, hands, and feet; and behavioral problems that are likened to obsessive compulsive disorder (3). AS is caused by loss of function of the maternally inherited allele of the E3 ubiquitin ligase UBE3A. UBE3A is subject to tissuespecific genomic imprinting; although both alleles are expressed in most tissues, the paternally inherited allele is repressed in the brain (4-6). Imprinted expression of UBE3A is thought to occur as a result of reciprocal expression of a long noncoding antisense transcript, UBE3A-ATS, which is part of a >600-kb transcript initiating at the differentially methylated PWS imprinting center (IC) located in exon 1 of the SNURF-SNRPN gene (7-9). PWS is associated with the loss of several species of small nucleolar RNAs (snoRNAs) (10); however, its genetic basis is currently unknown, and there is no mouse model that recapitulates all features of PWS.Mouse models of AS have proved significant in studying important aspects of the AS disease mechanism. There are, however, differences in the tissue specificity of the transcript that harbors UBE3A-ATS between humans and mice (11), indicating that the timing and mechanism of UBE3A repression may diverge between these species. The ability to study the developmental timing and mechanism of brain-specific repression of the paternal UBE3A allele in a model of human development is critical for better understanding the AS disease process and for using live neurons from patients with AS to discover previously undescribed therapeutic interventions. Here, we have developed such a model via human induced pluripotent stem cell (iPSC)-technology. ResultsHu...

Wnt-ligands are among key morphogens that mediate patterning of the anterior territories of the developing brain in mammals. We qualified the role of Wnt-signals in regional specification and subregional organization of the human telencephalon using human pluripotent stem cells (hPSCs). One step neural conversion of hPSCs using SMAD inhibitors leads to progenitors with a default rostral identity. It provides an ideal biological substrate for investigating the role of Wnt signaling in both anteroposterior and dorso-ventral processes. Challenging hPSCneural derivatives with Wnt-antagonists, alone or combined with sonic hedgehog (Shh), we found that Wntinhibition promote both telencephalic specification and ventral patterning of telencephalic neural precursors in a dose-dependent manner. Using optimal Wnt-antagonist and Shh-agonist signals we produced human ventraltelencephalic precursors, committed to differentiation into striatal projection neurons both in vitro and in vivo after homotypic transplantation in quinolinate-lesioned rats. This study indicates that sequentially organized Wntsignals play a key role in the development of human ventral telencephalic territories from which the striatum arise. In addition, the optimized production of hPSCderived striatal cells described here offers a relevant biological resource for exploring and curing Huntington disease.

Huntington's disease (HD) is characterized by a late clinical onset despite ubiquitous expression of the mutant gene at all developmental stages. How mutant huntingtin impacts on signalling pathways in the pre-symptomatic period has remained essentially unexplored in humans due to a lack of appropriate models. Using multiple human embryonic stem cell lines derived from blastocysts diagnosed as carrying the mutant huntingtin gene by pre-implantation genetic diagnosis, we explored early developmental changes in gene expression using differential transcriptomics, combined with gain and loss of function strategies. We demonstrated a down-regulation of the HTT gene itself in HD neural cells and identified three genes, the expression of which differs significantly in HD cells when compared with wild-type controls, namely CHCHD2, TRIM4 and PKIB. Similar dysregulation had been observed previously for CHCDH2 and TRIM4 in blood cells from patients. CHCHD2 is involved in mitochondrial function and PKIB in protein kinase A-dependent pathway regulation, which suggests that these functions may be precociously impacted in HD.

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from polyglutamine expansion in the huntingtin (HTT) protein and for which there is no cure. Although suppression of both wild type and mutant HTT expression by RNA interference is a promising therapeutic strategy, a selective silencing of mutant HTT represents the safest approach preserving WT HTT expression and functions. We developed small hairpin RNAs (shRNAs) targeting single nucleotide polymorphisms (SNP) present in the HTT gene to selectively target the disease HTT isoform. Most of these shRNAs silenced, efficiently and selectively, mutant HTT in vitro. Lentiviral-mediated infection with the shRNAs led to selective degradation of mutant HTT mRNA and prevented the apparition of neuropathology in HD rat's striatum expressing mutant HTT containing the various SNPs. In transgenic BACHD mice, the mutant HTT allele was also silenced by this approach, further demonstrating the potential for allele-specific silencing. Finally, the allele-specific silencing of mutant HTT in human embryonic stem cells was accompanied by functional recovery of the vesicular transport of BDNF along microtubules. These findings provide evidence of the therapeutic potential of allele-specific RNA interference for HD.